These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17031483)

  • 1. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges.
    Montané E; Sallés M; Barriocanal A; Riera E; Costa J; Tena X
    Clin Rheumatol; 2007 Sep; 26(9):1527-9. PubMed ID: 17031483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.
    El Mansouri L; Couchouron T; Le Roux G; Dugast C; Burtin F; Albert JD; Perdriger A; Hassouni NH; Chalès G
    Joint Bone Spine; 2009 Jul; 76(4):421-3. PubMed ID: 19457692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
    Akgül Ö; Kılıç G; Kılıç E; Cüce İ; Özgöçmen S
    Rheumatol Int; 2014 Mar; 34(3):443-4. PubMed ID: 23263496
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.
    Thiéfin G; Morelet A; Heurgué A; Diebold MD; Eschard JP
    Joint Bone Spine; 2008 Dec; 75(6):737-9. PubMed ID: 18693125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
    Cohen JD; Ferreira R; Jorgensen C
    J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
    Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
    Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
    [No Abstract]   [Full Text] [Related]  

  • 12. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.
    Giardina AR; Ferrante A; Ciccia F; Impastato R; Miceli MC; Principato A; Triolo G
    Rheumatol Int; 2010 Sep; 30(11):1437-40. PubMed ID: 19851772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
    Andreu JL; Otón T; Sanz J
    Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
    Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.